INS and obesity disorder: Specifically, activated JNK phosphorylates insulin receptor substrates (IRS-1/IRS-2) on serine residues (e.g., Ser-307), impairing their tyrosine phosphorylation and thus disrupting insulin signaling in obesity and insulin resistance models [25].